仝小林院士治疗糖尿病肾脏疾病大量白蛋白尿期验案1例
A case report of the treatment of diabetic kidney disease at the stage of macroalbuminuria by Academician Tong Xiaolin
DOI:10.13463/j.cnki.jlzyy.2022.05.024
扫 描 看 全 文
1.中国中医科学院广安门医院,北京 100053
2.北京中医药大学,北京 100029
扫 描 看 全 文
谢伟楠, 鲍婷婷, 黄一珊, 等. 仝小林院士治疗糖尿病肾脏疾病大量白蛋白尿期验案1例[DB/OL].(2023-09-15)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.13463/j.cnki.jlzyy.2022.05.024
XIE Weinan, BAO Tingting, HUANG Yishan, et al. A case report of the treatment of diabetic kidney disease at the stage of macroalbuminuria by Academician Tong Xiaolin[DB/OL].(2023-09-15)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.13463/j.cnki.jlzyy.2022.05.024
谢伟楠, 鲍婷婷, 黄一珊, 等. 仝小林院士治疗糖尿病肾脏疾病大量白蛋白尿期验案1例[DB/OL].(2023-09-15)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.13463/j.cnki.jlzyy.2022.05.024 DOI:
XIE Weinan, BAO Tingting, HUANG Yishan, et al. A case report of the treatment of diabetic kidney disease at the stage of macroalbuminuria by Academician Tong Xiaolin[DB/OL].(2023-09-15)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.13463/j.cnki.jlzyy.2022.05.024 DOI:
糖尿病肾脏疾病(diabetic kidney disease,DKD)临床上以持续性白蛋白尿和(或)估算肾小球滤过率(estimated glomerular filtration rate,eGFR)进行性下降为主要特征,是一种较为常见的糖尿病微血管并发症。糖尿病肾脏疾病患者病情进展至大量白蛋白尿期时,由于需要考虑患者的心、肾功能等,使用药物时会受到限制。仝小林院士根据多年临床经验,在“治未病”和“络病”理论指导下,提出该病的核心病机是气虚络瘀,其病理特点为“虚、瘀、浊”,治疗上提倡将益气活血通络贯穿治疗的始终。通过对仝小林院士治疗的1例糖尿病肾脏疾病大量白蛋白尿期的整理分析,总结其临床用方、用量经验。
Diabetic kidney disease (DKD) is clinically characterized by the symptom of persistent albuminuria and/or progressive decline in estimated glomerular filtration rate (eGFR), and is a relatively common microvascular complication of diabetes mellitus. As it progresses to the stage of macroalbuminuria, its medication will be subject to some restrictions due to the need to consider the patients’ heart and kidney functions. Based on years of clinical experience and under the guidance of the theories of preventive treatment of diseases and collateral diseases, Academician Tong Xiaolin concludes that its core pathogenesis is qi deficiency and collateral stasis, and its pathological characteristics are deficiency, blood stasis, and turbidity. Accordingly, he advocates replenishing qi, activating blood circulations and dredging collaterals throughout the treatment of the disease. This paper reports and analyzes a case of diabetic kidney disease with macroalbuminuria treated by Tong Xiaolin, in a bid to summarize his clinical experience in formulating prescriptions and determining proper dosages.
糖尿病肾脏疾病大量白蛋白尿期中医药疗法经验总结仝小林
diabetic kidney diseasestage of macroalbuminuriatraditional Chinese medicineexperience summaryTong Xiaolin
中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏病防治指南(2021年版)[J].中华糖尿病杂志, 2021, 13(8): 762-784.
International Diabetes Federation. IDF Diabetes Atlas. https://diabetesatlas.org/data/en/shttps://diabetesatlas.org/data/en/s. [DB/OL]. 2021-11-08.
仝小林.消渴六论[J].中医杂志, 2001(4): 252-253.
王新苗, 杨浩宇, 顾成娟, 等.黄芪、水蛭粉、大黄治疗糖尿病肾病经验: 仝小林三味小方撷萃[J].吉林中医药, 2020, 40(1): 5-7.
罗金丽, 顾成娟, 王涵.大黄、淫羊藿、生麻黄治疗肾功能不全经验: 仝小林三味小方撷萃[J].吉林中医药, 2020, 40(4): 434-436.
仝小林.糖络杂病论[M].3版.北京: 科学出版社, 2020.
中华医学会肾脏病学分会专家组.糖尿病肾脏疾病临床诊疗中国指南[J].中华肾脏病杂志, 2021, 37(3): 255-304.
周强, 甄仲, 刘桂芳, 等.糖尿病肾病之中医临证经验荟萃[J].北京中医药, 2010, 29(7): 563-565.
仝小林.维新医集[M].上海: 上海科技出版社, 2020: 20-30.
王涵, 周强, 仝小林.仝小林治疗糖尿病并发症应用黄芪经验[J].环球中医药, 2013, 6(4): 272-274.
于涵, 余海源, 牟爱敏.丹参对糖尿病肾病保护机制的研究进展[J].世界中医药, 2021, 16(7): 1161-1165.
逄冰, 刘文科, 闫韶花, 等.仝小林教授应用大黄黄连泻心汤验案举隅[J].新中医, 2012, 44(12): 171-173.
徐坤元, 顾成娟.生黄芪、泽泻、大黄治疗肾性水肿: 仝小林三味小方撷萃[J].吉林中医药, 2020, 40(10): 1276-1278.
黄颖, 吴思敏, 赵玲.大黄治疗糖尿病肾病有效性的系统评价[J].黑龙江中医药, 2021, 50(2): 86-89.
刘吉尧, 徐霜霜, 曾海文, 等.水蛭对糖尿病肾病的疗效及安全性的Meta分析[J].实用中医内科杂志, 2021, 35(5): 137-139, 157.
王青, 赵林华, 邸莎.黄芪的临床应用及其用量探究[J].吉林中医药, 2018, 38(12): 1450-1454.
潘韦韦, 金美英, 崔振海, 等.丹参的临床应用及其用量探究[J].吉林中医药, 2019, 39(6): 722-725.
毕超然, 张鹏, 朴春丽.大黄临床应用及其用量[J].吉林中医药, 2019, 39(1): 28-31.
沈仕伟, 邸莎, 韦宇, 等.水蛭临床应用及其用量[J].吉林中医药, 2019, 39(3): 313-316.
0
浏览量
8
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构